Implementing perioperative immunotherapy for head and neck cancer after KEYNOTE-689: questions and challenges
Brianna Brammer, Jennifer H Gross, Brian J Boyce, Nabil F Saba, Nicole C Schmitt · 2025
Read Implementing perioperative immunotherapy for head and neck cancer after KEYNOTE-689: questions and challenges by Brianna Brammer, Jennifer H Gross, Brian J Boyce, Nabil F Saba, Nicole C Schmitt (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776188.txt.
Description
Brianna Brammer and co-authors present a 2025 commentary on using immune therapy around the time of surgery for head and neck cancer. A large trial recently met its main goal, showing patients stayed free of cancer events longer with the added drug. The drug is now approved in the United States for resectable cases with a set marker.
Approval is major progress, but many questions remain before the approach is fully in place. The authors sum up the trial's design and results, then work through the open issues. Those include who gains most, how long to treat, and how teams should change their routines. The piece guides clinics through the shift.
Catalog record
| CREATOR | Brianna Brammer, Jennifer H Gross, Brian J Boyce, Nabil F Saba, Nicole C Schmitt |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |